U.S. Markets open in 5 hrs 21 mins
  • S&P Futures

    3,685.25
    +31.00 (+0.85%)
     
  • Dow Futures

    29,475.00
    +190.00 (+0.65%)
     
  • Nasdaq Futures

    11,332.00
    +103.75 (+0.92%)
     
  • Russell 2000 Futures

    1,700.20
    +18.10 (+1.08%)
     
  • Crude Oil

    82.09
    +0.86 (+1.06%)
     
  • Gold

    1,681.70
    +13.10 (+0.79%)
     
  • Silver

    19.13
    +0.42 (+2.23%)
     
  • EUR/USD

    0.9847
    +0.0028 (+0.2856%)
     
  • 10-Yr Bond

    3.7470
    0.0000 (0.00%)
     
  • Vix

    31.25
    +1.07 (+3.55%)
     
  • GBP/USD

    1.1178
    +0.0055 (+0.4918%)
     
  • USD/JPY

    144.3010
    -0.1420 (-0.0983%)
     
  • BTC-USD

    19,570.90
    +197.80 (+1.02%)
     
  • CMC Crypto 200

    447.16
    +1.18 (+0.26%)
     
  • FTSE 100

    6,928.38
    +46.79 (+0.68%)
     
  • Nikkei 225

    25,937.21
    -484.84 (-1.83%)
     

Voyager Therapeutics' Stock Jumps As FDA Lifts Clinical Hold For Huntington's Disease Gene Therapy

·1 min read
  • Today FDA has removed the clinical hold on one more gene therapy study, this time for Voyager Therapeutics Inc's (NASDAQ: VYGR) investigational new drug application for VY-HTT01, a gene therapy candidate for Huntington's disease (HD).

  • The agency has confirmed that the company may proceed with its planned Phase 1/2 clinical trial.

  • The decision comes after a comprehensive review of the Chemistry, Manufacturing, and Controls information previously submitted to the FDA.

  • Voyager plans to initiate VYTAL, a Phase 1/2 clinical trial of VY-HTT01, this year.

  • VYTAL Phase 1/2 trial is a dose-escalation study to evaluate the safety and tolerability of VY-HTT01 in patients with early manifest Huntington's disease.

  • Secondary endpoints include disease biomarkers and clinical outcome measures.

  • VY-HTT01 is a gene therapy designed to reduce the expression of huntingtin, thereby altering disease progression.

  • It includes adeno-associated virus capsid and a proprietary transgene that harnesses the canonical RNA interference pathway to knock down levels of HTT mRNA selectively.

  • Earlier today, the FDA removed the clinical hold on uniQure NV's (NASDAQ: QURE) hemophilia B gene therapy program.

  • Price Action: VYGR shares are moving 12.6% higher at $5.25 on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.